naive patients in India. The emergence of viral mutants resistant to the different classes of ARV therapy is one of the major concerns and results in treatment failure. These resistant mutants exhibit genotypic mutations in the genes of interest [mainly reverse transcriptase (RT) and protease]; these mutations are well characterized in subtype B strains, but data about non-B subtypes are scanty.
M
OLECULAR CHARACTERIZATION OF HIV helped in identifying the three distinctive subgroups of HIV-1, namely M, N, and O, with the A through K subdivisions of group M and circulating recombinant forms (CRFs). The distribution of these subtypes and CRFs in different parts of the world has epidemiological and diagnostic implications. In addition, it helps in vaccine design. Among these subtypes and CRFs, HIV-1 subtype C has the greatest global frequency. More than 50% of newly diagnosed HIV infections worldwide are related to HIV-1 subtype C.
India, the second largest populous country in the world, has reported an estimated 4 million cases of HIV-1 infection with predominantly subtype C. Few cases of subtype B, A, and CRF01 AE have been reported. India is now planning to launch an antiretroviral (ARV) access program to give ARV therapy free of cost. Four classes, namely, nucleoside and nonnucleoside reverse transcriptase inhibitors (NRTIs, NNRTIs), protease inhibitors (PIs), and fusion inhibitors, are now available to treat HIV-1 infection, of which only the fusion inhibitors are not yet marketed in India. Therefore, it is of particular importance to characterize the local subtypes and CRFs distribution of HIV 1 isolates from untreated cases and also to detect the polymorphism substitutions and potential resistance mutations in drug-before being used for sequence studies. Viral RNA was extracted using the High Pure Nucleic Acid Kit (Roche); the RNA was used in reverse transcription polymerase chain reaction (RT-PCR) of RT, protease, and env (C2/V3) genes using two sets of primers in a GeneAmp PCR System 9700 (Applied Biosystems, Foster City, CA) thermal cycler. The outer and inner primers for RT, protease, and env regions are described in Table 1 . Extractions and amplifications were carried out in the Haffkine Institute. The fragments obtained were sequenced on both strands using the CEQ DTCS Quick Start Kit on an automated sequencer Beckman CEQ 2000 DNA Analyzer System in the University of Bordeaux as previously described. 1 The derived nucleotide sequences of the RT, protease, and env C2/V3 regions were aligned by the Clustal W 1.74 multiple sequence alignment program with known reference strains of group M and N pooled from the HIV-1 gene databank (http://hivweb.lanl.gov/). Phylogenetic trees were inferred using the neighbor-joining method from matrix distances calculated after gapstipping of alignments, with a Kimura two-parameter algorithm. The mutations involved in antiretroviral resistance are available on the International AIDS Society (IAS) and the French Agence Nationale de Recherche sur le SIDA (ANRS) databank (http://www.iasusa.org and http://hivfrenchresistance.org). GenBank accession numbers for the sequences reported in this study are AY525953-AY526078, AY515728-AY515849, and AY525845-AY525952.
The mean age of the studied population was 30.4 years and the median TCD4 T cell count was 594/l (range 403-1586).
In the study population, subtype C is largely predominant (Fig. 1) followed by A-C intersubtype recombinants, one subtype A, and one CRF01_AE. The predominance of subtype C in India has already been reported by different authors [2] [3] [4] [5] [6] ; the presence of A-C intersubtype recombinants is in agreement with previous work. 7 Although the introduction of the B subtype in Bombay has been reported, 8 this study did not identify the B subtype in any case. Subtype A and CRF01 AE are rarely observed in Bombay as has been pointed out in India. 4 The amino acid substitutions in the RT are presented in Figure (M184V) could be detected in two isolates of subtype C; these mutations are known to be associated with resistance to 3TC, a molecule belonging to the NRTI group of drugs.
Concerning the protease gene (Fig. 3) , the most frequently (above 50%) observed positions of amino acid substitutions for subtype C are 12, 15, 19, 36, 63, 69, 89, and 93. Substitutions at positions of secondary mutations to PIs are rare (10, 20, 46, 71, 82) or exhibit a high polymorphism (36, 63). No major resistance mutation to PIs could be noted.
With the confirmed predominance of subtype C in Bombay, the main result of this study is the presence of resistance mutations to an NRTI in isolates from patients who denied having received treatment with ARV. It is difficult to find an explanation for these mutations: did the patients, in fact, receive ARV at improper doses or as a monotherapy with 3TC or as a bitherapy including 3TC? We must take into account the high level of TCD4 cells of the population studied (median: 594/l), indicating that the corresponding individuals have been quite recently infected; therefore, it might signify that the individuals whose HIV-1 isolates bear mutations of resistance to 3TC have been infected through a horizontal route by patients receiving or having received ARV including 3TC and experiencing viral failure. It is clear from this study, carried out in an untreated sample of cases from Bombay, that the prevalence of resistant mutations is low (1.6%), under the alert cut off (5%), which has been defined by the ad hoc working group of the World Health Organization (WHO). Since more patients of Bombay will receive ARV within HAART (two NRTI including 3TC plus one NNRTI) in the near future, it will be important to check if the prevalence of resistant mutations is stable or increasing. 
